MAPT and early-onset autosomal dominant Alzheimer disease: Several PROTACs targeting tau have been discovered, including TH006, which reduced tau levels in vitro, and in a mouse model of Alzheimer’s disease, lessened the neurotoxicity of Aβ [30].